ARCT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
18.3M
+518.4%
3.0M
+43.6%
2.1M
-71.4%
7.2M
-58.0%
17.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
18.3M
+518.4%
3.0M
+43.6%
2.1M
-71.4%
7.2M
-58.0%
17.2M
Operating Expenses
27.5M
-3.6%
28.5M
-8.0%
31.0M
-19.5%
38.5M
+14.4%
33.7M
R&D
17.0M
-3.0%
17.5M
-18.6%
21.5M
-12.0%
24.5M
+5.2%
23.3M
SG&A
10.5M
-4.6%
11.0M
+16.1%
9.5M
-32.5%
14.0M
+34.9%
10.4M
Operating Income
-9185000
+64.0%
-25545000
+11.7%
-28931000
+7.6%
-31307000
-89.6%
-16512000
EBITDA
-8584000
+65.5%
-24902000
+11.9%
-28273000
+7.7%
-30625000
-94.5%
-15749000
Net Income
-7414000
+68.8%
-23785000
+11.8%
-26964000
+7.3%
-29079000
-116.2%
-13448000
EPS (Basic)
$-0.26
+69.0%
$-0.84
+11.6%
$-0.95
+7.8%
$-1.03
-110.2%
$-0.49
EPS (Diluted)
$-0.26
+69.0%
$-0.84
+11.6%
$-0.95
+7.8%
$-1.03
-110.2%
$-0.49
Shares (Diluted)
28.4M
+0.1%
28.4M
+0.0%
28.4M
+1.1%
28.1M
+3.4%
27.2M
Arcturus Therapeutics (ARCT) — Financials